Search Results

Below are the search engine results of your query.

Showing 1-10 of 16 results for "R142b"

Vertrel™ Specialty Fluids

Vertrel™ specialty fluids act as fluorinated solvents, cleaners, and more.

The Chemours Company Reports First Quarter 2017 Results; Significant Earnings Improvements in All Segments

First Quarter 2017 Highlights Net Sales of $1.4 billion , up 11%, including impacts from divestitures Net Income of $150 million , up $99 million with EPS of $0.79 , up $0.51 per diluted share Adjusted EBITDA of $285 million , up 123%, demonstrating margin improvement across all segments Adjusted Net Income of $142 million , up $131 million with Adjusted EPS of $0.75 , up $0.69 per diluted share A...

The Chemours Company Reports Fourth Quarter and Full Year 2019 Results

Full Year 2019 Results In-line with Updated Guidance Full Year 2019 Results Net Sales of $5.5 billion Net Income of $(52) million with EPS of $(0.32) Adjusted Net Income of $419 million with Adjusted EPS of $2.51 Adjusted EBITDA of $1.02 billion Free Cash Flow of $169 million Returned $486 million to shareholders through share repurchases and dividends Fourth Quarter 2019 Results Net Sales of $1.4...

Consent Order Compliance

Documents have been submitted by The Chemours Company.

Chemours Receives NYSE Notice Regarding Delayed Form 10-K Filing

On March 18, 2024, The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) received notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023, with the Securities and Exchange Commission (the “SEC”).

Vertrel™ XSi Specialty Fluid

Vertrel™ XSi is specially designed for use in the medical industry.

The Chemours Company Reports Third Quarter 2022 Results

Continued strength in APM and TSS despite uncertain macroeconomic conditions The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, today announced its financial results for the third quarter 2022.

The Chemours Company Reports First Quarter 2019 Results

Continuing to Aggressively Return Capital to Shareholders First Quarter 2019 Highlights Net Sales of $1.4 billion Net Income of $94 million, with EPS of $0.55 Adjusted Net Income of $109 million, with Adjusted EPS of $0.63 Adjusted EBITDA of $262 million Returned $261 million to shareholders through share repurchases The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leadi...

The Chemours Company Reports Strong Second Quarter Results and Increases Full-Year 2017 Outlook

Second Quarter 2017 Highlights Net Sales of $1.6 billion , up 15% Net Income of $161 million , up $179 million with EPS of $0.84 , up $0.94 per diluted share Adjusted EBITDA of $361 million , up $174 million , driven by strong year-over-year volume and price improvement in Titanium Technologies and Fluoroproducts Adjusted Net Income of $166 million , up $117 million with Adjusted EPS of $0.87 , up...

The Chemours Company Reports First Quarter 2024 Results

The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (“TT”), Thermal & Specialized Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced its financial results for the first quarter 2024.